Tafasitamab‑Cxix Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 200 mg

Reference Brands: Monjuvi (USA), Minjuvi (EU)

Category: Oncology Cancer Care

Tafasitamab‑cxix is a humanized, Fc‑engineered monoclonal antibody targeting the CD19 protein on B‑cell surfaces. It is used intravenously in combination with other therapies (e.g., lenalidomide) to treat relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) in adults not eligible for stem cell transplant. The antibody recruits immune effector cells to kill malignant B cells. It is supplied as a 200 mg powder for infusion. Tafasitamab represents a modern immunotherapy option in aggressive B‑cell lymphomas. Tafasitamab‑cxix is available in Injection and strengths such as 200 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Tafasitamab‑cxix is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Tafasitamab‑cxix can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Tafasitamab‑cxix is a targeted cancer immunotherapy in the form of a humanized, Fc‑modified monoclonal antibody directed against the CD19 antigen, a protein expressed on the surface of B‑cells, including malignant cells in B‑cell non‑Hodgkin lymphomas. By binding to CD19, tafasitamab flags cancerous B‑cells for destruction by the immune system, enhancing immune‑mediated cytotoxic mechanisms like antibody‑dependent cellular cytotoxicity (ADCC) and antibody‑dependent cellular phagocytosis (ADCP). It is primarily indicated for treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant, typically administered in combination with lenalidomide during early cycles and followed by tafasitamab monotherapy until disease progression or unacceptable toxicity. The drug is supplied as a lyophilized 200 mg vial for intravenous infusion by healthcare professionals. Tafasitamab has been approved in the United States as Monjuvi and in the European Union and United Kingdom as Minjuvi (tafasitamab) with conditional authorizations. Its development represents an important step in expanding therapeutic options for patients with aggressive B‑cell lymphomas refractory to standard treatments, offering a biologic approach that leverages immune engagement against tumor cells.